# MDalgorithms Inc. Unveils Breakthrough Clinical Trial Results for Al-Powered Personalized Hair Loss Treatment

Study Confirms Al-Driven Customization Significantly Improves Hair Growth and Scalp Health in Women

March 2025 233 Volume 24 • Issue 3

Copyright © 2025

**ORIGINAL ARTICLE** 

Journal of Drugs in Dermatology

# Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial

Vinay Bhardwaj PhD,<sup>a</sup> Nancy Rodgers PhD,<sup>a</sup> Oded Harth,<sup>b</sup>Yoram Harth MD FAAD<sup>b</sup>

\*SGS, Clinical Research, Health & Nutrition – Cosmetics and Hygiene, Richardson, TX
bMDalgorithms Inc., San Francisco, CA

#### **ABSTRACT**

Hair loss affects up to 50% of women and 80% of men. The high costs and wait times for professional consultations lead many to seek one-size-fits-all solutions that are frequently ineffective. This study tested an artificial intelligence (AI) model for customizing non-medicated hair loss treatments. In a 24-week trial, 38 women with self-reported hair thinning received personalized product kits based on AI analysis of scalp images and questionnaires. Treatments included various combinations of topical serums, shampoos, oral supplements, and marine collagen peptides. Of the 27 participants who completed the study, significant improvements were observed in hair growth, coverage, and thickness (*P*<0.001 for all). Hair shedding decreased by 37.3% at 12 weeks and 32.4% at 24 weeks. Scalp transepidermal water loss was reduced by 61.5% at 12 weeks and 69% at 24 weeks. Scanning electron microscopy showed improved hair texture. Participants reported overall hair improvement (88.9%), better scalp health (85.2%), and less hair brittleness (92.6%) (*P*<0.001 for all). No adverse events were reported. The AI-driven platform effectively delivered personalized hair loss treatments, suggesting a data-driven, customized, and accessible self-served alternative for hair loss management.

J Drugs Dermatol. 2025;24(3):233-238. doi:10.36849/JDD.8611

San Francisco, California Mar 5, 2025 (Issuewire.com) - MDalgorithms Inc., a leader in Al-driven personalized dermatological care, today announced the publication of groundbreaking clinical trial results in the March 2025 issue of the *Journal of Drugs in Dermatology*. The study is the first third-party clinical trial evaluating its MDhair.co Al-personalized hair loss treatments for women demonstrates that MDalgorithms' proprietary platform significantly enhances hair growth, reduces shedding, and improves scalp health—offering a cost-effective and accessible alternative to expensive dermatologist visits and generic over-the-counter treatments.

## Key Clinical Findings: A Game-Changer for Hair Loss Treatment

In a **24-week**, **single-blind trial** involving 38 women with self-reported hair thinning—27 of whom completed the study—the Al-driven platform tailored treatment kits based on scalp imaging and a comprehensive dermatological questionnaire. The results showed:

Significant Hair Growth & Density Improvements – Expert grading confirmed statistically significant increases in hair volume, thickness, and scalp coverage (P < 0.001).

**37.3% Reduction in Hair Shedding at 12 Weeks** – Participants saw a **32.4% reduction in shedding by 24 weeks**, marking a major improvement in hair retention.

Stronger Scalp Barrier Function – Measurements of transepidermal water loss (TEWL) were reduced by 61.5% at 12 weeks and 69% at 24 weeks, reflecting a healthier, more resilient scalp.

#### Overwhelmingly Positive User Feedback -

- 88.9% reported visible hair improvement
- 85.2% noted better scalp health
- 92.6% observed reduced hair brittleness

**Advanced Imaging Confirms Efficacy** – Scanning electron microscopy (**SEM**) showed clear improvements in hair texture and structural integrity.

## **Transforming Hair Loss Care with Al-Powered Personalization**

"These results validate the power of our Al-driven platform to deliver **personalized**, **multi-targeted treatments** that outperform traditional one-size-fits-all approaches," said **Oded Harth**, **CEO of MDalgorithms Inc.** "Our technology, leveraging advanced **computer vision and deep learning**, offers a **scalable**, **affordable alternative to conventional dermatologist visits**, providing superior outcomes for women struggling with hair loss."

Unlike generic solutions, **MDalgorithms**' treatment kits are uniquely tailored to each individual's hair loss profile, combining:

- Dermatologist-formulated topical serums
- Advanced scalp-nourishing shampoos
- Targeted oral supplements
- Marine collagen peptides for enhanced hair strength

Importantly, the study reported no treatment-related adverse events, further reinforcing the safety and efficacy of MDalgorithms' personalized approach.

#### A Mission to Democratize Dermatology

"With hair loss affecting millions of women, our goal is to **make high-quality, customized treatment accessible to all**," added **Dr. Yoram Harth, Chief Medical Officer of MDalgorithms**. "This study not only proves the **clinical effectiveness** of our Al-powered solution but also positions MDalgorithms as a **transformative force** in modern dermatology."

#### **Learn More**

For full study details and information on MDalgorithms' **Al-powered hair loss solutions**, visit **www.MDhair.co** and **www.MDalgorithms.com**.

#### **About MDalgorithms Inc.**

MDalgorithms Inc. is pioneering Al-powered personalized dermatology, leveraging advanced

machine learning and a proprietary database of over 47,000 scalp images to create **customized**, **effective**, **and affordable treatments** for hair and skin concerns. By combining **cutting-edge technology with medical expertise**, MDalgorithms is **revolutionizing dermatological care** for a global audience.





#### **Media Contact**

MDalgorithms Inc.

\*\*\*\*\*\*\*@mdalgorithms.com

Source: MDalgorithms Inc.

See on IssueWire